

From the Chief Medical Officer
Professor Sir Michael McBride



HSS(MD)38/2025

FOR ACTION

Chief Executives, Public Health Agency/HSC Trusts/NIAS
Chief Operating Officer, SPPG
GP Medical Advisers, SPPG
All General Practitioners and GP Locums (for onward
distribution to practice staff)
OOHs Medical Managers (*for onward distribution to staff*)
RQIA (*for onward transmission to all independent providers
including independent hospitals*)

Castle Buildings
Stormont Estate
BELFAST
BT4 3SQ

Tel: 028 9052 0563
Email: cmooffice@health-ni.gov.uk

Our Ref: HSS(MD)38/2025
Date: 8 December 2025

PLEASE SEE ATTACHED FULL CIRCULATION LIST

Dear Colleague

MHRA DRUG SAFETY UPDATE: Mesalazine and idiopathic intracranial hypertension

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued the below Drug Safety Update.

Healthcare Professionals are asked to note and action the advice for healthcare professionals, advice for healthcare professionals to provide to patients and recommendations contained within the Drug Safety Update.

Please find the link to the complete **MHRA Drug Safety Update** included below:

[Mesalazine and idiopathic intracranial hypertension](#)

Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for idiopathic intracranial hypertension are being added to the product information for all mesalazine products.

If idiopathic intracranial hypertension occurs in patients, discontinuation of mesalazine should be considered.

Reporting advice

Healthcare professionals, patients, and caregivers are asked to submit reports using the Yellow Card scheme electronically using:

- the [Yellow Card website](#).
- the Yellow Card app; download from the [Apple App Store](#) or [Google Play Store](#)
- some clinical IT systems for healthcare professionals

When reporting suspected adverse drug reactions, please provide as much information as possible, including information about medical history, any concomitant medication, onset timing, and treatment dates.

For queries or more information, please contact info@mhra.gov.uk.

You can subscribe to the MHRA new Safety Roundup bulletin [here](#). The latest MHRA Safety Roundup is available at the following link: [MHRA Safety Roundup](#).

Yours sincerely



PROFESSOR SIR MICHAEL MCBRIDE
Chief Medical Officer



PROFESSOR CATHY HARRISON
Chief Pharmaceutical Officer

Circulation List

Director of Public Health/Medical Director, Public Health Agency (*for onward distribution to all relevant health protection staff*)
Assistant Director Public Health (Health Protection), Public Health Agency
Director of Nursing, Public Health Agency
Assistant Director of Pharmacy and Medicines Management, SPPG (*for onward distribution to SPPG Pharmacy and Medicines Management Team and community pharmacists*)
Directors of Pharmacy HSC Trusts
Director of Social Care and Children, SPPG
Family Practitioner Service Leads, SPPG (*for cascade to GP Out of Hours services*)
Medical Directors, HSC Trusts (*for onward distribution to all Consultants, Occupational Health Physicians and School Medical Leads*)
Nursing Directors, HSC Trusts (*for onward distribution to all Community Nurses, and Midwives*)
Directors of Children's Services, HSC Trusts
RQIA (*for onward transmission to all independent providers including independent hospitals*)
Regional Medicines Information Service, Belfast HSC Trust
Regional Pharmaceutical Procurement Service, Northern HSC Trust
Professor Kenda Crozier, Head of School of Nursing and Midwifery QUB
Andrea Shepherd, Head of School of Nursing, Ulster University
Heather Finlay, Head of HSC Clinical Education Centre
Maurice Devine, Open University
Professor Paul McCarron, Head of School of Pharmacy and Pharmaceutical Sciences, Ulster University
Professor Gavin Andrews, Head of School, School of Pharmacy, QUB
Postgraduate Pharmacy Dean, NI Centre for Pharmacy Learning and Development, QUB
Michael Donaldson, Head of Dental Services, SPPG (*for distribution to all General Dental Practitioners*)
Raymond Curran, Head of Ophthalmic Services, SPPG (*for distribution to Community Optometrists*)
Trade Union Side
Clinical Advisory Team
Louise McMahon, Director of Integrated Care, SPPG
Dr Camille Harron, NIMDTA
Prof Pascal McKeown, QUB
Prof Alan Smyth, QUB
Prof Peter Bazira, Head of Medical School, UU
Dr Kathy Cullen, Director of the Centre for Medical Education at QUB

This letter is available on the Department of Health website at

<https://www.health-ni.gov.uk/topics/professional-medical-and-environmental-health-advice/hssmd-letters-and-urgent-communications>